 | ||||||||||||
| ||||||||||||
| ||||||||||||
| ||||||||||||
 | ||||||||||||
 | ||||||||||||
 | ||||||||||||
| ||||||||||||||||||||
|
|
Click on the titles below for current clinical trials information and eligibility criteria. Marqibo® (vincristine sulfate injection, OPTISOME™) Phase II: Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia (rALLy) Phase II: Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma Alocrest™ (vinorelbine tartrate injection, OPTISOME™) Phase I: Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease Menadione Topical Lotion Phase 1: Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash For more information, prospective patients or their physicians should send an email to info@hanabiosciences.com | ||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
